Home › Research › Biomarkers
Independent validation of the PrecivityAD2 blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment
Justine Coppinger, Tim West, Kris M. Kirmess, Ilana Fogelman, Sutapa Ray, Philip B. Verghese, Joel B. Braunstein, Kevin E. Yarasheski. npj Dementia, 2025-09-04
Topic: Amyloid, tau and blood-test diagnosis
Using blood samples from the publicly available ADNI research cohort (191 people with mild cognitive impairment or dementia), this study found the PrecivityAD2 blood test agreed with amyloid PET scans about 91% of the time. Note: although the dataset was independent, all authors are C2N Diagnostics employees or consultants with equity in the company, a disclosed conflict of interest worth keeping in mind.
Key findings
- 191 ADNI participants over age 55 with amyloid PET within 6 months of blood draw
- Overall accuracy 91% (95% CI 86-94%), sensitivity 90%, specificity 92%
- AUC-ROC of 0.95
Why it matters
The PrecivityAD2 blood test matched brain PET scans 91% of the time in detecting amyloid pathology in 191 people with cognitive impairment. This diagnostic validation does not demonstrate whether identifying or treating amyloid improves symptoms or slows disease progression.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants191
- Effect sizeAccuracy 91% (95% CI 86-94%); sensitivity 90%, specificity 92%; AUC-ROC 0.95
- Evidence strengthModerate
Limitations
All authors are employees/consultants of C2N Diagnostics with financial ties/equity in the test's maker, a disclosed conflict of interest; secondary analysis of a public research cohort (ADNI), not an independent clinical sample.
How this study scored 58/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomised / blinded and indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 36 of the 62 points we could judge it on, which is 58 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (npj Dementia) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 191 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 36 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 36 of the 62 points we could judge it on is 58 out of 100. |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Coppinger, J., West, T., Kirmess, K. M., Fogelman, I., Ray, S., Verghese, P. B., et al. (2025). Independent validation of the PrecivityAD2 blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment. npj Dementia.
Vancouver
Coppinger J, West T, Kirmess KM, Fogelman I, Ray S, Verghese PB, et al. Independent validation of the PrecivityAD2 blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment. npj Dementia. 2025.
BibTeX
@article{coppinger2025-7d747d82,
author = {Coppinger, Justine and West, Tim and Kirmess, Kris M. and Fogelman, Ilana and Ray, Sutapa and Verghese, Philip B. and Braunstein, Joel B. and Yarasheski, Kevin E.},
title = {{Independent validation of the PrecivityAD2 blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment}},
journal = {npj Dementia},
year = {2025}
}
Related studies in Biomarkers
Also tagged “biomarkers”
821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.